The United Kingdom and the United States have agreed to a landmark bilateral deal that will guarantee zero levies on British drug products entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to raise funding on drugs through the public health system. This commitment ensures that import taxes on these vital exports will stay at nothing for a timeframe of the next three years.
This agreement follows recent warnings to hike import taxes on branded drug imports, with potential rates discussed up to one hundred percent.
"This deal between the Britain strengthens the worldwide climate for new treatments and establishes long-overdue balance to transatlantic pharmaceutical trade," an announcement declared.
Commercial Significance
Medicines are one of the the United Kingdom's biggest export categories to the United States, which is easily the primary buyer for large UK drugmakers.
Trade data reveal that in the one-year period to the end of last September, the UK shipped pharmaceutical products totaling over eleven billion pounds to the US. This amount accounted for 17.4% of all goods exports in that period.
"This agreement safeguards jobs, boosts funding and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a minister commented.
Key British Pledges
The deal includes several key commitments from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it judges new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a goal to double overall public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be capped at fifteen percent. Last year, rebates topped twenty percent.
Industry Background
This agreement follows a ongoing row between the sector and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by assertions that American customers were paying several times more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several major pharmaceutical investments in the UK have been delayed or abandoned, while major expansions have been pledged toward American operations.
One official stated that the NHS had to invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its resources over the last ten years.
